The prognosis of patients diagnosed with cancer after starting hemodialysis appears comparable to that of patients with cancer in the general population.
First-line pembrolizumab “has consistent antitumor activity and safety” in patients with advanced urothelial carcinoma who are potentially ineligible for platinum‐based chemotherapy, researchers found ...